FDA Grants Fast Track Designation to Safusidenib for IDH1-Mutant Glioma

The FDA granted a fast track designation to safusidenib (Nuvation Bio), an investigational oral, brain-penetrant inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), for the treatment of patients with IDH1-mutant glioma. The decision was supported by findings from the safusidenib clinical program, including updated phase 2 clinical trial results which demonstrated durable responses with longer follow-up.¹

Fast track designation facilitates the development and review of drugs intended to treat serious conditions and address an unmet medical need. It provides opportunities for more frequent communication with the FDA and could allow rolling review of a future marketing application if relevant criteria are met. The designation does not establish efficacy or indicate that safusidenib has been approved.²

Updated Results Show Durable Activity

The multicenter, open-label, single-arm phase 2 J201 trial (NCT04458272) evaluated safusidenib in 27 patients in Japan with chemotherapy- and radiotherapy-naïve, IDH1-mutant World Health Organization grade 2 glioma. Participants received safusidenib 250 mg twice daily.³

In the analysis, safusidenib produced a confirmed objective response rate (ORR) of approximately 44.4% according to Response Assessment in Neuro-Oncology criteria for low-grade gliomas. This included partial and minor responses. The confirmed clinical benefit rate was 81.5%.

Median progression-free survival (PFS) was not reached, and the estimated probability of remaining progression-free at 24 months was 87.9%. The median time to response was 12.7 months, suggesting that radiographic responses can develop gradually during treatment.³

Subsequent results reported by the manufacturer after a median follow-up of 38.8 months showed a confirmed ORR of approximately 51.9%. Median PFS remained unreached, and the estimated 36-month PFS rate was 79.1%. Only 1 patient who had achieved an objective response subsequently experienced disease progression. There were new safety signals identified during the additional follow-up.¹

The updated efficacy figures have not yet been reported in a peer-reviewed publication. Interpretation is also limited by the trial’s 27-patient population, lack of a comparator arm, and enrollment of patients who had not received chemotherapy or radiation.

Safety Findings Define Monitoring Priorities

In the published phase 2 analysis, 96.3% of patients experienced a treatment-emergent adverse event (TEAE). Most events were grade 1 or 2, whereas treatment-related grade 3 or higher TEAEs occurred in 18.5% of patients.³

The most frequently reported TEAEs were alopecia (59.3%), arthralgia (55.6%), skin hyperpigmentation (48.1%), as well as increased alanine aminotransferase (40.7%) and aspartate aminotransferase (33.3%) levels. Nine patients required a dose reduction, and 16 experienced an AE that led to a treatment interruption.

Two patients discontinued treatment because of treatment-related abnormal hepatic function. Both events resolved following dose interruption or medical management. There were no grade 5 events reported.³

These findings make hepatic laboratory monitoring and assessment of persistent musculoskeletal symptoms relevant considerations as safusidenib advances through clinical development.

Safusidenib Enters an Evolving Treatment Landscape

IDH1 mutations alter cellular metabolism by promoting production of D-2-hydroxyglutarate, an oncometabolite involved in epigenetic dysregulation and glioma development. Safusidenib is designed to selectively inhibit mutant IDH1 while achieving penetration across the blood-brain barrier.³

The treatment landscape already includes vorasidenib (Voranigo; Servier), an oral inhibitor of mutant IDH1 and IDH2, which was FDA-approved in 2024 for patients 12 years or older with grade 2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation following surgery. The approval was supported by the randomized phase 3 INDIGO trial (NCT04164901).⁴

Safusidenib differs by selectively targeting mutant IDH1. Its eventual place in therapy will depend on randomized efficacy, long-term safety, and the populations in which it is studied. Evidence will also be needed to determine whether it offers a role after progression on another IDH inhibitor.

Phase 3 Development Will Determine Clinical Role

The pivotal phase 3 SIGMA study (NCT05303519) is evaluating safusidenib as maintenance therapy after standard treatment in patients with IDH1-mutant astrocytoma and high-risk features. Its randomized portion is expected to enroll approximately 300 patients and compare safusidenib with placebo.⁵

An exploratory cohort will evaluate the drug in patients with grade 3 IDH1-mutant oligodendroglioma who have undergone surgery without subsequent chemotherapy or radiation. Additional studies are planned in newly diagnosed grade 2 disease and among patients whose disease has progressed on vorasidenib.¹

For pharmacists specializing in oncology, future evaluation should focus on the drug’s twice-daily administration, hepatic safety, dose-modification requirements, and positioning relative to vorasidenib. The fast track designation could accelerate regulatory interactions, but the ongoing trials will determine whether safusidenib provides a clinically meaningful addition to targeted treatment for IDH1-mutant glioma.

REFERENCES

1. Nuvation Bio granted FDA Fast Track designation for safusidenib for treatment of IDH1-mutant glioma. Nuvation Bio Inc. News release. August 20, 2026. Accessed August 21, 2026. https://investors.nuvationbio.com/news/news-details/2026/Nuvation-Bio-Granted-FDA-Fast-Track-Designation-for-Safusidenib-for-Treatment-of-IDH1-Mutant-Glioma/default.aspx

2. Fast Track. FDA. Updated August 13, 2024. Accessed August 21, 2026. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

3. Arakawa Y, Saito R, Kanemura Y, et al. Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas. Neuro Oncol. 2026;28(3):717-727. doi:10.1093/neuonc/noaf258

4. FDA approves vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. FDA. News release. August 6, 2024. Accessed August 21, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation

5. A study of safusidenib in IDH1-mutant glioma maintenance (SIGMA). ClinicalTrials.gov identifier: NCT05303519. Updated August 13, 2026. Accessed August 21, 2026. https://clinicaltrials.gov/study/NCT05303519